RhumbLine Advisers
LKFT

RhumbLine Advisers’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

RhumbLine Advisers’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Sell
7,297
-84
-1% -$2.38K ﹤0.01% 3241
2026
Q1 		$221K Buy
7,381
+409
+6% +$13.5K ﹤0.01% 3071
2025
Q4 		$228K Buy
6,972
+3,372
+94% +$109K ﹤0.01% 3116
2025
Q3 		$125K Sell
3,600
-255
-7% -$8.16K ﹤0.01% 3434
2025
Q2 		$108K Sell
3,855
-33
-0.8% -$885 ﹤0.01% 3502
2025
Q1 		$97.7K Sell
3,888
-935
-19% -$23.6K ﹤0.01% 3404
2024
Q4 		$133K Hold
4,823
– – ﹤0.01% 3386
2024
Q3 		$139K Buy
4,823
+245
+5% +$6.67K ﹤0.01% 3395
2024
Q2 		$113K Buy
4,578
+814
+22% +$23.1K ﹤0.01% 3481
2024
Q1 		$121K Buy
3,764
+728
+24% +$27.1K ﹤0.01% 3382
2023
Q4 		$123K Hold
3,036
– – ﹤0.01% 3378
2023
Q3 		$105K Buy
3,036
+55
+2% +$2.14K ﹤0.01% 3443
2023
Q2 		$121K Buy
+2,981
New +$122K ﹤0.01% 3444

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RhumbLine Advisers's LKFT Position: Q2 2026 in Review

RhumbLine Advisers reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 1.1% in Q2 2026, selling an estimated $2.38K and leaving 7,297 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

RhumbLine Advisers first reported a position in LKFT in Q2 2023 and has held it in 13 quarters since. The position peaked at $228K in Q4 2025. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • RhumbLine Advisers held 7,297 shares of Lakefront Biotherapeutics American Depositary Shares worth $219K as of Q2 2026.
  • RhumbLine Advisers sold 84 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $2.38K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3241 holding.
  • RhumbLine Advisers first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Lakefront Biotherapeutics American Depositary Shares position peaked at $228K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.